Today analysts at Mizuho Securities reiterated Laboratory Corp. Of America Holdings’s (NYSE:LH) shares as ‘Neutral’ in a report released to investors.
According to Mizuho Securitiess price target of 139 on the company’s stock this indicates the broker now believes there is an increase of 0.1% from Laboratory Corp. Of America Holdings’s current price of 138.86.
In the last year Laboratory Corp. Of America Holdings’s stock price has increased by 31.25% from 105.8 to 138.86.
The number of Laboratory Corp. Of America Holdings shares in issue is 103,000,000 which have a current share price of 138.86 bringing Laboratory Corp. Of America Holdings’s market capitalisation to 14.30B USD.
The 52 week high of shares in Laboratory Corp. Of America Holdings is 141.32 while the 52 week low for the company’s shares is 106.01. The businesses 50 day moving average is 133.14 and its 200 day moving average is 132.91.
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.